Mesenteric Visceral Lipectomy Improves Glucose Tolerance in Patients With Type 2 Diabetes: A Pilot Study
Authors' conclusion
Mesenteric visceral lipectomy (MVL) shows potential as a novel, minimally invasive approach to improve glycemic control in patients with suboptimally controlled T2D, but further controlled studies are needed to confirm these findings and better understand the potential benefits of MVL.
Study context
- Population
- Individuals with obesity and poorly controlled T2D (HbA1c 8.9% ± 0.2%; FPG 211 ± 12 mg/dL)
- Participants
- 7 individuals
- Outcome
- Glycaemic control: HbA1c and FPG after MVL
- Follow-up
- Month 6
Methodological detailssingle-group
- Single-group
Main finding
As reported in the abstract
HbA1c declined from baseline 8.9% ± 0.2% (P = .01)
7.7%
FPG declined from baseline 211 ± 12 mg/dL (P < .01)
140 mg/dL
Further findings
TIR (CGM) · months 6 and 12
- Baseline
- 22%
- Month 6 (P < .001)
- 74%
- Month 12 (P < .05)
- 50%
Suppression of endogenous (hepatic) glucose production · months 6 and 12
- Baseline
- 29%
- Month 6 (P < .05)
- 45%
- Month 12 (P < .01)
- 43%
Whole-body (muscle) insulin-mediated glucose disposal · months 6 and 12
- Did not change significantly
Body weight and percent body fat · month 12
- Body weight decreased slightly (P < .05)
- 106.8 to 103.3 kg
- Percent body fat decreased slightly (P < .05)
- 33.3 to 31.6%
Hepatic fat content (hydrogen-1 magnetic resonance spectroscopy) · month 12
- Decreased significantly (P < .005)
- 23.9 ± 3.7 to 19.1 ± 3.4%
Insulin secretion and disposition index during OGTT · month 6
- Increased more than 2-fold (both P < .05); improvements persisted at 12 months
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →